AI in Healthcare October 17, 2024
The U.S. Food and Drug Administration has its hands full making sure medical AI products are safe, efficacious and trustworthy before they hit the market. The rise of ever-more-innovative iterations of the technology—not least generative AI—is only adding to the burden.
But fear not. The agency is prepared to handle its duties and responsibilities to the best of its considerable abilities. It just can’t do everything for everyone all at once. In fact, it could use a hand from other stakeholders.
This comes through between the lines of a special communication published in JAMA Oct. 15. Senior-authored by FDA commissioner Robert Califf, MD, the paper describes 10 duties the agency must juggle as part of the job. Here are...
Today's Sponsors
Today's Sponsor